002198 Guangdong Jiaying Pharmaceutical
- 6.43
- +0.08+1.26%
Guangdong Jiaying Pharmaceutical News
The function and indication of Guangdong Jiaying Pharmaceutical (002198.SZ) Double-Throat Wind-Dispersing Granules are clearing heat and detoxifying, reducing swelling and benefiting the throat.
Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform on July 17 that the dual-purpose throat and wind dispersal produced by the company has the following functions: clearing heat and detoxifying, reducing swelling and soothing the throat. It is used for throat and mouth ulcers, gum swelling and pain, sinusitis, skin ulcers and other conditions caused by lung and stomach fever and toxicity.
As of July 10th, Guangdong Jiaying Pharmaceutical (002198.SZ) had a total of 22,404 shareholders.
On July 12th, Gelunhui reported that Guangdong Jiaying Pharmaceutical (002198.SZ) stated on the investor interaction platform that as of July 10, 2024, according to the shareholder roster issued by the China Securities Depository and Clearing Co., Ltd., the company has 22,404 shareholders.
Subdued Growth No Barrier To Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Price
Guangdong Jiaying Pharmaceutical: Guangdong Jiaying Pharmaceutical Co., Ltd.'s performance forecast for the first half of 2024.
Guangdong Jiaying Pharmaceutical (002198.SZ) issued a profit warning, with a projected net income of 46-58 million yuan, a year-on-year decrease of 68%-75%.
Jiaying Pharmaceutical (002198.SZ) announced its performance forecast for the first half of 2024, with an expected net income attributable to shareholders of the listed company of 4.6 million yuan to 5.8 million yuan, a year-on-year decrease of 68%-75%. After deducting non-recurring gains and losses, the net income is expected to be 0.8 million yuan to 1.2 million yuan, a year-on-year decrease of 93%-95%. In the first half of 2024, in response to the various challenges facing the company's operation, the company actively maintained the market sales of its leading products and worked to maintain market share. At the same time, the company made every effort to develop the market sales of potential exclusive varieties and relied on existing pharmaceutical products.
Guangdong Jiaying Pharmaceutical (002198.SZ) plans to distribute 0.5 yuan per 10 shares on June 21 for ex-rights and ex-dividends.
Jiaying Pharmaceutical (002198.SZ) announced that it plans to distribute an annual equity of 0.5 yuan (tax included) per 10 shares to all shareholders in 2023. The ex-rights and ex-dividend date is June 21, 2024.
Some May Be Optimistic About Guangdong Jiaying Pharmaceutical's (SZSE:002198) Earnings
Jiaying Pharmaceutical (002198.SZ) announced first-quarter results, net profit of 5.1822 million yuan, a decrease of 57.47%
Jiaying Pharmaceutical (002198.SZ) released its report for the first quarter of 2024, achieving 944 operating income during the reporting period...
Guangdong Jiaying Pharmaceutical (SZSE:002198) Delivers Shareholders Favorable 9.6% CAGR Over 3 Years, Surging 16% in the Last Week Alone
Guangdong Jiaying Pharmaceutical Co., Ltd (SZSE:002198) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely
Do Guangdong Jiaying Pharmaceutical's (SZSE:002198) Earnings Warrant Your Attention?
Jiaying Pharmaceutical (002198.SZ): As of January 19, 2024, the number of shareholders of the company was 24,225
Gelonghui, January 23 | Jiaying Pharmaceutical (002198.SZ) said on the investor interactive platform that as of January 19, 2024, according to the shareholder register issued by Zhongdeng, the number of shareholders of the company was 24,225.
Jiaying Pharmaceutical (002198.SZ): As of January 10, 2024, the number of shareholders of the company was 24,572
Gelonghui, January 11 | Jiaying Pharmaceutical (002198.SZ) said on the investor interactive platform that as of January 10, 2024, according to the shareholder register issued by Zhongdeng, the number of shareholders of the company was 24,572.
Jiaying Pharmaceutical (002198.SZ): Downstream customers are mainly pharmaceutical commercial companies, pharmacy chains, hospitals, etc.
Gelonghui, December 11丨Jiaying Pharmaceutical (002198.SZ) said on the investor interactive platform that the company's downstream customers are mainly pharmaceutical commercial companies, pharmacy chains and hospitals.
Jiaying Pharmaceutical (002198.SZ): The main cold products include heavy inspirational tablets, yingqiao detoxifying granules, and orange red phlegm cough granules
On December 6, Gelonghui, Jiaying Pharmaceutical (002198.SZ) stated on the investor interactive platform that the company currently mainly focuses on proprietary Chinese medicine products. Among them, cold products mainly include heavy sentimental tablets, Yinjao detoxifying granules, and orange red phlegm cough granules.
Jiaying Pharmaceutical (002198.SZ): At present, Huaqingyuan's production work is progressing smoothly and in an orderly manner
Gelonghui November 21丨Jiaying Pharmaceutical (002198.SZ) stated on the investor interactive platform that the production department of Huaqingyuan Company formulates production plans and work arrangements based on the current development situation and future plans, and also combines its own production system and quality system, and carries out production and related work in strict accordance with the plan. At present, Huaqingyuan's production work is progressing smoothly and in an orderly manner. For specific data, you can pay attention to the annual report disclosed by the company at that time. I hope you can continue to pay attention to and support our company.
Has Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Jiaying Pharmaceutical (002198.SZ): There is no clear plan for developing weight loss and slimming prescriptions at this stage
Gelonghui September 22丨Jiaying Pharmaceutical (002198.SZ) stated on the investor interactive platform that the company has no clear plans to develop weight loss and slimming prescriptions at this stage. The company's board of directors and management are exploring the re-production or investment in re-development of other products in the approval, further optimizing the company's product structure, thereby promoting the company's high-quality development.
Jiaying Pharmaceutical (002198.SZ): Net profit increased 112.32% in the first half of the year to 18.2485 million yuan
Gelonghui, August 25, 丨 Jiaying Pharmaceutical (002198.SZ) announced its 2023 semi-annual report. Operating income for the reporting period was 257 million yuan, up 4.28% year on year; net profit attributable to shareholders of listed companies was 18.2485 million yuan, up 112.32% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 16.7709 million yuan, up 90.49% year on year; basic earnings per share were 0.0360 yuan.
Do Its Financials Have Any Role To Play In Driving Guangdong Jiaying Pharmaceutical Co., Ltd's (SZSE:002198) Stock Up Recently?
Analysis
Price Target
No Data
